<DOC>
	<DOCNO>NCT00685633</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth prostate cancer cell . Antihormone therapy , bicalutamide , may lessen amount androgen make body . Enzastaurin may stop growth tumor cell block enzymes need cell growth . It yet know whether give bicalutamide together enzastaurin effective bicalutamide alone treat prostate cancer . PURPOSE : This randomized phase II trial study bicalutamide see well work compare give bicalutamide together enzastaurin treat patient prostate cancer .</brief_summary>
	<brief_title>Bicalutamide With Without Enzastaurin Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare two regimen proportion patient undetectable prostate-specific antigen ( PSA ) level ( &lt; 0.2 ng/mL ) 44 week . Secondary - To assess proportion patient PSA decline &gt; 85 % 44 week combination therapy arm compare bicalutamide monotherapy arm . - To assess distribution best PSA response study arm . - To assess time PSA progression time PSA nadir arm study . - To assess duration PSA response arm study . - To characterize PSA slope , , treatment . - To evaluate safety tolerability enzastaurin hydrochloride patient population . - To determine whether Gleason score prior hormonal therapy effect PSA response treatment . OUTLINE : This multicenter study . Patients stratify accord Gleason score ( ≤ 6 v 7 v 8-10 ) prior hormonal therapy ( yes v ) . Patients randomize 1 2 treatment arm . - Arm A : - Weeks 1-12 : Patients observe without treatment . Patients prostate-specific antigen ( PSA ) rise &gt; 50 % baseline nadir ( whichever low ) rise least 5 ng/mL , confirm repeat PSA least 2 week later , may start bicalutamide end week 12 discretion treat physician . - Weeks 13-44 : Patients rise PSA ≥ 50 % baseline nadir , PSA rise least 5 ng/mL confirm repeat PSA least 2 week later , remove study . Patients receive oral bicalutamide daily . Patients achieve PSA decline ≥ 50 % absence toxicity may continue receive bicalutamide 72 week . - Arm B : - Weeks 1-12 : Patients receive oral enzastaurin hydrochloride twice daily . Patients PSA rise &gt; 50 % baseline nadir , rise least 5 ng/mL , confirm repeat PSA least 2 week later , may start bicalutamide end week 12 discretion treat physician . - Weeks 13-44 : Patients PSA rise ≥ 50 % baseline nadir , rise least 5 ng/mL , confirm repeat PSA least 2 week later , remove study . Patients receive oral enzastaurin twice daily oral bicalutamide daily . Patients achieve PSA decline ≥ 50 % absence toxicity may continue combination therapy 72 week . After completion study treatment , patient follow every 3 month 5 year , every 6 month 10 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer Hormonesensitive disease , evidence serum total testosterone level &gt; 150 ng/dL No evidence metastatic disease physical exam , CT abdomen/pelvis ( MRI ) , chest xray CT scan bone scan within 6 week prior randomization Underwent prior definitive surgery radiotherapy Must evidence biochemical failure primary therapy subsequent progression determine 1 following : Prostatespecific antigen ( PSA ) ≥ 0.4 ng/mL ( case radical prostatectomy ) PSA rise ≥ 2 ng/mL nadir PSA ( case radiotherapy ) Baseline PSA must least 2 ng/mL great 50 ng/mL PSA doubling time ( PSADT ) &lt; 12 month PATIENT CHARACTERISTICS : ECOG performance status 0 1 Granulocytes ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 Serum creatinine normal creatinine clearance ≥ 60 mL/min Serum total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN SGOT SGPT &lt; 2.5 time ULN PT/INR normal Fertile patient must use effective barrier contraception least 3 month completion study treatment No gastrointestinal ( GI ) tract disease result : inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) No history allergic reaction attribute compound similar chemical biologic composition enzastaurin hydrochloride bicalutamide No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement A history malignancy permit patient predict diseasefree 2 year PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior salvage therapy intent cure ( i.e. , surgery , radiotherapy , local ablative procedure ) More 4 week since prior prophylactic radiotherapy prevent gynecomastia More 1 year since prior therapy modulate testosterone level ( luteinizinghormone releasinghormone agonists/antagonists antiandrogens ) unless neoadjuvant adjuvant set No 5 alpha reductase inhibitor , ketoconazole , megestrol acetate , systemic steroid , herbal supplement PSA value collection At least 14 day since prior enzymeinducing antiepileptic drug ( EIAEDs ) Patients must begin EIAED therapy study allow remain No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticoagulant therapy Low dosage acetyl salicylic acid ≤ 325 mg/day allow No concurrent investigational agent anticancer therapy ( i.e. , chemotherapy , immunotherapy , radiotherapy , surgery cancer , experimental medication ) No history allergic reaction attribute compound similar chemical biologic composition enzastaurin bicalutamide Prior neoadjuvant and/or adjuvant therapy ≤ 4 week prior randomization ( i.e. , hormone , chemotherapy , vaccine , experimental agent ) allow PSA rise PSADT document testosterone level &gt; 150 ng/dL</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>